Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR to Present at Upcoming Scientific Meeting and Investor Conference

GlobeNewswire February 6, 2018

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

GlobeNewswire January 8, 2018

ProQR Announces Extraordinary General Meeting of Shareholders

GlobeNewswire December 27, 2017

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

GlobeNewswire November 29, 2017

ProQR to Present at the Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 21, 2017

ProQR Announces Results for the Third Quarter of 2017

GlobeNewswire November 20, 2017

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

GlobeNewswire November 14, 2017

ProQR Announces Proposed Public Offering of Ordinary Shares

GlobeNewswire November 13, 2017

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

GlobeNewswire November 13, 2017

ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board  

GlobeNewswire November 9, 2017

ProQR to Present at EuroTIDES Conference

GlobeNewswire October 31, 2017

ProQR Announces Management Change and Key Promotions

GlobeNewswire October 26, 2017

ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

GlobeNewswire October 24, 2017

ProQR to Present at the Chardan Inaugural Gene Therapy Conference

GlobeNewswire October 6, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  September 26, 2017

What's The Thesis On ProQR Now, After Promising Phase 1 Data?

Benzinga.com  September 26, 2017

22 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  September 26, 2017

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

GlobeNewswire September 25, 2017

ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

GlobeNewswire September 21, 2017

ProQR to Present at Two Investor Conferences in September

GlobeNewswire September 21, 2017